57 research outputs found
Regulation of blood platelet function by the AGC family of protein kinases
Upon vascular injury, platelets aggregate at the site of blood vessel injury to form a hemostatic plug maintaining the physiological integrity of the vascular system. Platelets respond to a variety of extracellular stimuli to undergo a rapid aggregation response, releasing active granule contents and leading to a rapidly growing thrombus. During the adhesion, activation, and aggregation of platelets at an injured site, the endothelium responds by limiting the size and growth of the hemostatic plug or thrombus, or even reversing platelet reactivity. These responses are defined as endothelial thromboregulation. There are three primary (and functionally independent) pathways during the early stages of thromboregulation by which the endothelium controls platelet reactivity (1) nitric oxide (NO); (2) prostacyclin (PGI₂ ); and (3) the ectonucleotidase CD39. NO and PGI2 stimulate signalling cascades that result in the activation of the AGC family of Ser/Thr protein kinases (PKA, PKG and PKC). Once activated these kinase blunt platelet function through the phosphorylation of signalling proteins requested for activation. In this study, the role of AGC family kinases and their signaling cascades in regulating platelet function was assessed. The experimental data produced during this study demonstrate new insights in to the regulation of these kinases in platelets. More specifically it was found that1. Peroxynitrite, a derivative of NO, regulated platelet function and particularly cytoskeletal rearrangement through PKC-dependent phosphorylation of VASPSer²³⁹⁄¹⁵⁷2. NO-mediated signalling in platelets had a requirement for PKC.3. Multiple forms of PKA are present in platelets, which are differentially localised.4. The potential regulation of platelet function by PKA is mediated through Akinase anchoring proteins.5. Lipid rafts may play an important role in platelet regulation by NO and PKG.In summary, this studies present insights of the factors regulating AGC kinases in blood platelets
Targeting cAMP Signalling to Combat Cardiovascular Diseases Platelet myosin light chain phosphatase: keeping it together
Abstract MLCP (myosin light chain phosphatase) regulates platelet function through its ability to control myosin IIa phosphorylation. Recent evidence suggests that MLCP is a de facto target for signalling events stimulated by cAMP. In the present mini-review, we discuss the mechanisms by which cAMP signalling maintains MLCP in an active state to control platelet contractile machinery
cGMP signaling inhibits platelet shape change through regulation of the RhoA-Rho Kinase-MLC phosphatase signaling pathway
Background: Platelet shape change, spreading and thrombus stability require activation of the actin cytoskeleton contractile machinery. The mechanisms controlling actin assembly to prevent unwanted platelet activation are unclear. Objectives: We examined the effects of nitric oxide on the signaling pathways regulating platelet actinmyosin activation. Results: S-nitrosoglutathione (GSNO) inhibited thrombin-induced platelet shape change and myosin phosphorylation of the myosin light chain (MLC).
Because thrombin stimulates phospho-MLC through the RhoA/ ROCK dependent inhibition of MLC phosphatase (MLCP) we examined the effects of NO on this pathway.
Thrombin caused the GTP loading and activation of RhoA, leading to the ROCK-mediated phosphorylation of MLCP on threonine 853 (thr853), which is known to inhibit phosphatase activity. Treatment of platelets with GSNO blocked ROCK-mediated increases in phosphoMLCPthr853 induced by thrombin. This effect was mimicked by the direct activator of protein kinase G, 8-pCPT-PET-cGMP, and blocked by the inhibition of guanylyl cyclase, but not inhibitors of protein kinase A. Further exploration of the mechanism demonstrated that GSNO stimulated the association of RhoA with protein kinase G (PKG) and the inhibitory phosphorylation (serine188) of RhoA in a cGMP-dependent manner. Consistent with these observations, in vitro experiments revealed that recombinant PKG caused direct phosphorylation of RhoA. The inhibition of RhoA by GSNO prevented ROCK-mediated phosphorylation and inhibition of MLCP activity. Conclusions: These data suggest novel crosstalk between the NO-cGMP-PKG and RhoA/ROCK signaling pathways to control platelet actin remodeling
Alterations in Platelet Alpha-Granule Secretion and Adhesion on Collagen under Flow in Mice Lacking the Atypical Rho GTPase RhoBTB3
Typical Rho GTPases, such as Rac1, Cdc42, and RhoA, act as molecular switches regulating various aspects of platelet cytoskeleton reorganization. The loss of these enzymes results in reduced platelet functionality. Atypical Rho GTPases of the RhoBTB subfamily are characterized by divergent domain architecture. One family member, RhoBTB3, is expressed in platelets, but its function is unclear. In the present study we examined the role of RhoBTB3 in platelet function using a knockout mouse model. We found the platelet count, size, numbers of both alpha and dense granules, and surface receptor profile in these mice were comparable to wild-type mice. Deletion of Rhobtb3 had no effect on aggregation and dense granule secretion in response to a range of agonists including thrombin, collagen, and adenosine diphosphate (ADP). By contrast, alpha-granule secretion increased in mice lacking RhoBTB3 in response to thrombin, collagen related peptide (CRP) and U46619/ADP. Integrin activation and spreading on fibrinogen and collagen under static conditions were also unimpaired; however, we observed reduced platelet accrual on collagen under flow conditions. These defects did not translate into alterations in tail bleeding time. We conclude that genetic deletion of Rhobtb3 leads to subtle alterations in alpha-granule secretion and adhesion to collagen without significant effects on hemostasis in vivo
Atherogenic Lipid Stress Induces Platelet Hyperactivity Through CD36-Mediated Hyposensitivity To Prostacyclin-; The Role Of Phosphodiesterase 3A
Prostacyclin (PGI2) controls platelet activation and thrombosis through a cyclic adenosine monophosphate (cAMP) signalling cascade. However, in patients with cardiovascular diseases this protective mechanism fails for reasons that are unclear. Using both pharmacological and genetic approaches we describe a mechanism by which oxidised low density lipoproteins (oxLDL) associated with dyslipidaemia promote platelet activation through impaired PGI2 sensitivity and diminished cAMP signalling. In functional assays using human platelets, oxLDL modulated the inhibitory effects of PGI2, but not a PDE-insensitive cAMP analogue, on platelet aggregation, granule secretion and in vitro thrombosis. Examination of the mechanism revealed that oxLDL promoted the hydrolysis of cAMP through the phosphorylation and activation of phosphodiesterase 3A (PDE3A), leading to diminished cAMP signalling. PDE3A activation by oxLDL required Src family kinases, Syk and protein kinase C. The effects of oxLDL on platelet function and cAMP signalling were blocked by pharmacological inhibition of CD36, mimicked by CD36-specific oxidised phospholipids and ablated in CD36-/- murine platelets. The injection of oxLDL into wild type mice strongly promoted FeCl3 induced carotid thrombosis in vivo, which was prevented by pharmacological inhibition of PDE3A. Furthermore, blood from dyslipidaemic mice was associated with increased oxidative lipid stress, reduced platelet sensitivity to PGI2 ex vivo and diminished PKA signalling. In contrast, platelet sensitivity to a PDE-resistant cAMP analogue remained normal. Genetic deletion of CD36, protected dyslipidaemic animals from PGI2 hyposensitivity and restored PKA signalling. These data suggest that CD36 can translate atherogenic lipid stress into platelet hyperactivity through modulation of inhibitory cAMP signalling.
Recommended from our members
Platelet releasate promotes skeletal myogenesis by increasing muscle stem cell commitment to differentiation and accelerates muscle regeneration following acute injury
Aim: The use of platelets as biomaterials has gained intense research interest. However,
the mechanisms regarding platelet-mediated skeletal myogenesis remain to be established.
The aim of this study was to determine the role of platelet releasate in skeletal myogenesis
and muscle stem cell fate in vitro and ex vivo respectively.
Methods: We analysed the effect of platelet releasate on proliferation and differentiation of
C2C12 myoblasts by means of cell proliferation assays, immunohistochemistry, gene
expression and cell bioenergetics. We expanded in vitro findings on single muscle fibres by
determining the effect of platelet releasate on murine skeletal muscle stem cells using
protein expression profiles for key myogenic regulatory factors.
Results: TRAP6 and collagen used for releasate preparation had a more pronounced effect
on myoblast proliferation versus thrombin and sonicated platelets (P<0.05). In addition,
platelet concentration positively correlated with myoblast proliferation. Platelet releasate
increased myoblast and muscle stem cell proliferation in a dose-dependent manner, which
was mitigated by VEGFR and PDGFR inhibition. Inhibition of VEGFR and PDGFR ablated
MyoD expression on proliferating muscle stem cells, compromising their commitment to
differentiation in muscle fibres (P<0.001). Platelet releasate was detrimental for myoblast
fusion and affected differentiation of myoblasts in a temporal manner. Most importantly we
show that platelet releasate promotes skeletal myogenesis through the PDGF/VEGF-Cyclin
D1-MyoD-Scrib-Myogenin axis and accelerates skeletal muscle regeneration after acute
injury.
Conclusion: This study provides novel mechanistic insights on the role of platelet releasate
in skeletal myogenesis and set the physiological basis for exploiting platelets as biomaterials
in regenerative medicine
Author Correction: Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects (Scientific Reports, (2020), 10, 1, (4750), 10.1038/s41598-020-61531-z)
© 2020, The Author(s). The original version of this Article contained a typographical error in the spelling of the author Johannes Graumann, which was incorrectly given as Johannes Grauman. This has now been corrected in the PDF and HTML versions of the Article, and in the accompanying Supplementary Information file
Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects
Intensive diabetes control has been associated with increased mortality in type 2 diabetes (T2DM); this has been suggested to be due to increased hypoglycemia. We measured hypoglycemia-induced changes in endothelial parameters, oxidative stress markers and inflammation at baseline and after a 24-hour period in type 2 diabetic (T2DM) subjects versus age-matched controls. Case-control study: 10 T2DM and 8 control subjects. Blood glucose was reduced from 5 (90 mg/dl) to hypoglycemic levels of 2.8 mmol/L (50 mg/dl) for 1 hour by incremental hyperinsulinemic clamps using baseline and 24 hour samples. Measures of endothelial parameters, oxidative stress and inflammation at baseline and at 24-hours post hypoglycemia were performed: proteomic (Somalogic) analysis for inflammatory markers complemented by C-reactive protein (hsCRP) measurement, and proteomic markers and urinary isoprostanes for oxidative measures, together with endothelial function. Between baseline and 24 -hours after hypoglycemia, 15 of 140 inflammatory proteins differed in T2DM whilst only 1 of 140 differed in controls; all returned to baseline at 24-hours. However, elevated hsCRP levels were seen at 24-hours in T2DM (2.4 mg/L (1.2–5.4) vs. 3.9 mg/L (1.8–6.1), Baseline vs 24-hours, P < 0.05). In patients with T2DM, between baseline and 24-hour after hypoglycemia, only one of 15 oxidative stress proteins differed and this was not seen in controls. An increase (P = 0.016) from baseline (73.4 ng/mL) to 24 hours after hypoglycemia (91.7 ng/mL) was seen for urinary isoprostanes. Hypoglycemia resulted in inflammatory and oxidative stress markers being elevated in T2DM subjects but not controls 24-hours after the event
Acute hypertriglyceridemia induces platelet hyperactivity that is not attenuated by insulin in polycystic ovary syndrome.
Atherothrombosis is associated with platelet hyperactivity. Hypertriglyceridemia and insulin resistance (IR) are features of polycystic ovary syndrome (PCOS). The effect of induced hypertriglyceridemia on IR and platelet function was examined in young women with PCOS. Following overnight fasting, 13 PCOS and 12 healthy women were infused with saline or 20% intralipid for 5 hours on separate days. Insulin sensitivity was measured using a hyperinsulinemic euglycaemic clamp in the final 2 hours of each infusion. Platelet responses to adenosine diphosphate (ADP) and prostacyclin (PGI2) were measured by flow cytometric analysis of platelet fibrinogen binding and P-selectin expression using whole blood taken during each infusion (at 2 hours) and at the end of each clamp. Lipid infusion increased triglycerides and reduced insulin sensitivity in both controls (median, interquartile range ) (5.25 [3.3, 6.48] versus 2.60 [0.88, 3.88] mg kg(-1) min(-1), P<0.001) and PCOS (3.15 [2.94, 3.85] versus 1.06 [0.72, 1.43] mg kg(-1) min(-1), P<0.001). Platelet activation by ADP was enhanced and ability to suppress platelet activation by PGI2 diminished during lipid infusion in both groups when compared to saline. Importantly, insulin infusion decreased lipid-induced platelet hyperactivity by decreasing their response to 1 μmol/L ADP (78.7% [67.9, 82.3] versus 62.8% [51.8, 73.3], P=0.02) and increasing sensitivity to 0.01 μmol/L PGI2 (67.6% [39.5, 83.8] versus 40.9% [23.8, 60.9], P=0.01) in controls, but not in PCOS. Acute hypertriglyceridemia induced IR, and increased platelet activation in both groups that was not reversed by insulin in PCOS subjects compared to controls. This suggests that platelet hyperactivity induced by acute hypertriglyceridemia and IR could contribute athero-thrombotic risk. www.isrctn.org. Unique Identifier: ISRCTN42448814
Recommended from our members
Attenuation of oxidative stress-induced lesions in skeletal muscle in a mouse model of obesity-independent hyperlipidaemia and atherosclerosis through the inhibition of Nox2 activity
Obesity leading to hyperlipidaemia and atherosclerosis is recognised to induce
morphological and metabolic changes in many tissues. However, both hyperlipidaemia and
atherosclerosis can occur in the absence of obesity. The impact of the latter scenario on
skeletal muscle and liver is not understood sufficiently. In this regard, we used the
Apolipoprotein E-deficient (ApoE-/-) mouse model, an established model of hyperlipidaemia
and atherosclerosis, that does not become obese when subjected to a high-fat diet, to
determine the impact of Western-type diet (WD) and ApoE deficiency on skeletal muscle
morphological, metabolic and biochemical properties. To establish the potential of
therapeutic targets, we further examined the impact of Nox2 pharmacological inhibition on
skeletal muscle redox biology. We found ectopic lipid accumulation in skeletal muscle and
the liver, and altered skeletal muscle morphology and intramuscular triacylglycerol fatty acid
composition. WD and ApoE deficiency had a detrimental impact in muscle metabolome,
followed by perturbed gene expression for fatty acid uptake and oxidation. Importantly, there
was enhanced oxidative stress in the skeletal muscle and development of liver steatosis,
inflammation and oxidative protein modifications. Pharmacological inhibition of Nox2
decreased reactive oxygen species production and protein oxidative modifications in the
muscle of ApoE-/- mice subjected to a Western-type diet. This study provides key evidence to
better understand the pathophysiology of skeletal muscle in the context of hyperlipidaemia
and atherosclerosis and identifies Nox2 as a potential target for attenuating oxidative stress
in skeletal muscle in a mouse model of obesity-independent hyperlipidaemia
- …